Compare ILMN & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | LII |
|---|---|---|
| Founded | 1998 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 19.5B |
| IPO Year | 2000 | 1999 |
| Metric | ILMN | LII |
|---|---|---|
| Price | $116.78 | $483.76 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 13 |
| Target Price | $124.24 | ★ $596.75 |
| AVG Volume (30 Days) | ★ 1.9M | 426.3K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ 170.87 | 1.11 |
| EPS | 5.45 | ★ 22.79 |
| Revenue | $4,343,000,000.00 | ★ $5,195,300,000.00 |
| Revenue This Year | $6.52 | $6.90 |
| Revenue Next Year | $5.49 | $5.69 |
| P/E Ratio | ★ $22.26 | $22.30 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $68.70 | $443.19 |
| 52 Week High | $155.53 | $689.44 |
| Indicator | ILMN | LII |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 32.62 |
| Support Level | $114.88 | $481.66 |
| Resistance Level | $135.68 | $573.78 |
| Average True Range (ATR) | 4.50 | 18.56 |
| MACD | -0.21 | -8.59 |
| Stochastic Oscillator | 1.62 | 2.00 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.